Targeted attack on tough colon cancer before surgery
NCT ID NCT05510895
Summary
This study tested a combination of three targeted drugs (encorafenib, binimetinib, and cetuximab) given for 8 weeks before surgery to people with a specific genetic type of localized colon cancer (BRAF V600E mutated). The goal was to see if this 'neoadjuvant' approach could shrink tumors effectively and be safe. Only 2 people were enrolled in this completed Phase 2 trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, 20249, Germany
Conditions
Explore the condition pages connected to this study.